Stocks Health care RCKT
NASDAQ · Health careRocket Pharmaceuticals, Inc. (RCKT)
Rocket Pharmaceuticals, Inc. brought in $0 of revenue over the twelve months to June 30, 2026. It posted a net loss of $17.3M. In fiscal 2025 capital spending exceeded operating cash flow by $190.5M. At June 30, 2026 it held $224.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Key facts about Rocket Pharmaceuticals, Inc.
- Net worth
- Rocket Pharmaceuticals, Inc. has a market value (market cap) of $277.7M at the latest share price, and shareholders' equity of $368.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $223.1M. Over the 12 months to June 30, 2026: revenue $0, net loss $17.3M.
- Cash flow
- In fiscal 2025 operations used $190M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Rocket Pharmaceuticals, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Rocket Pharmaceuticals, Inc. does
Rocket Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RCKT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$223.1M | -$2.01 | -$190.5M |
| 2024 | $0 | -$258.7M | -$2.73 | -$215.6M |
| 2023 | $0 | -$245.6M | -$2.92 | -$211.4M |
| 2022 | $0 | -$221.9M | -$3.26 | -$186.5M |
| 2021 | $0 | -$169.1M | -$2.67 | -$128.8M |
| 2020 | $0 | -$139.7M | -$2.52 | -$95.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Rocket Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 30, 2026Passive stake changed SCHEDULE 13G/A
- October 6, 2026Material agreement8-KRocket Pharmaceuticals entered into a loan agreement with Hercules Capital for up to $150.0 million in senior secured term loans.
- September 15, 2026
- September 2, 2026Delisting notice 25-NSE
- August 27, 2026
- August 10, 2026
- August 10, 2026
- August 3, 2026
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- July 14, 2026
Insider trades
What the people running Rocket Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $415.6K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 5, 2026 | Wilson MartinGeneral Counsel | Sold | 53,389 | $127.8K |
| September 11, 2026 | Wilson MartinGeneral Counsel | Sold | 75,364 | $256.5K |
| August 18, 2026 | Shah GauravCEO | Sold | 2,293 | $7.8K |
| August 18, 2026 | Wilson MartinGeneral Counsel | Sold | 631 | $2.1K |
| August 13, 2026 | Wilson MartinGeneral Counsel | Sold | 3,493 | $11.8K |
| August 13, 2026 | Shah GauravCEO | Sold | 2,837 | $9.6K |
| August 11, 2026 | Chaudhuri SarbaniSee Remarks | Sold | 4,701 | $16.4K |
| August 11, 2026 | Stevens Christopher JamesChief Operating Officer | Sold | 36,658 | $128.3K |
Who owns RCKT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Roderick Wong, M.D.13D, may seek influence with 1 related filers | 17.6% | December 16, 2024 |
| Vanguard Portfolio Management13G, passive | 5.35% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 180 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Rtw Investments, LP | 17,687,772 | 0 |
| BlackRock, Inc. | 9,923,962 | +2,089,167 |
| Vanguard Portfolio Management LLC | 5,810,033 | +1,119,818 |
| Citigroup Inc | 4,865,551 | -242,157 |
| Marshall Wace, Llp | 4,029,262 | +990,547 |
| Millennium Management LLC | 4,000,344 | +882,220 |
| Newtyn Management, LLC | 4,000,000 | +834,100 |
| Maverick Capital Ltd | 3,923,963 | +356,591 |
| Vanguard Capital Management LLC | 3,784,387 | +8,651 |
| Aqr Capital Management LLC | 3,386,162 | +316,232 |
| Goldman Sachs Group Inc | 2,833,427 | +1,112,311 |
| Monaco Asset Management SAM | 2,480,468 | +422,165 |
| Geode Capital Management, LLC | 2,370,729 | +181,473 |
| Federated Hermes, Inc. | 2,304,207 | +1,280,460 |
| Jacobs Levy Equity Management, Inc | 1,974,896 | +1,558,363 |
| Jpmorgan Chase & Co | 1,988,413 | +1,192,189 |
| State Street Corp | 1,820,121 | -2,665,868 |
| Dimensional Fund Advisors LP | 1,125,500 | +837,236 |
| Morgan Stanley | 1,062,522 | -957,586 |
| Opaleye Management Inc. | 1,000,000 | +45,000 |
Insiders
14 insiders reported holding 3,746,027 shares in total, about $9.5M at the last price.
| Holder | Shares |
|---|---|
| Shah GauravCEO | 1,056,594 |
| Wilson MartinGeneral Counsel | 545,100 |
| Stevens Christopher JamesChief Operating Officer | 505,784 |
| Rizvi Syed Ali-aamirChief Medical Officer | 407,874 |
| Schwartz Jonathan DavidSee Remarks | 299,064 |
| Chaudhuri SarbaniSee Remarks | 262,809 |
| Southwell David PDirector | 204,522 |
| Militello JohnSee Remarks | 89,780 |
| Fong PeterDirector | 76,195 |
| Wong RoderickDirector, 10% owner | 75,499 |
Questions about RCKT
What does Rocket Pharmaceuticals, Inc. do?
Rocket Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as RCKT. Its shares trade on NASDAQ under the ticker RCKT.
What is Rocket Pharmaceuticals, Inc.'s net worth?
Rocket Pharmaceuticals, Inc. has a market value (market cap) of $277.7M at the latest share price, and shareholders' equity of $368.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Rocket Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $17.3M.
How much revenue does Rocket Pharmaceuticals, Inc. make?
Over the twelve months to June 30, 2026 Rocket Pharmaceuticals, Inc. reported revenue of $0.
When did Rocket Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from November 9, 2026.
When is Rocket Pharmaceuticals, Inc.'s next earnings report?
Rocket Pharmaceuticals, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare RCKT with
Follow RCKT
Get an email when Rocket Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Rocket Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.